UBS Group’s Zymeworks ZYME Stock Holding History

UBS Group’s Portfolio ZYME Stock Details ZYME Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-9,700	Closed	-$458K	–	9555
2020 Q4	$458K	Buy	+9,700	New	+$450K	﹤0.01%	4670

Other funds holding ZYME

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

BNP Paribas Asset Management Paris, France $99.8B AUM 45.22% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.56% 1-Year Est. Return

Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return

UBS Group's ZYME Position: Q2 2026 in Review

UBS Group reduced its Zymeworks (ZYME) stake by 33% in Q2 2026, selling an estimated $1.44M and leaving 115,095 shares worth $3.01M. The position accounts for ﹤0.01% of the portfolio, ranked #4693.

UBS Group first reported a position in ZYME in Q4 2017 and has held it in 33 quarters since. The position peaked at $7.34M in Q4 2025. 202 funds tracked by Wall St. Rank hold ZYME as of Q2 2026.

UBS Group held 115,095 shares of Zymeworks worth $3.01M as of Q2 2026.
UBS Group sold 56,684 Zymeworks shares in Q2 2026, an estimated $1.44M.
Zymeworks made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #4693 holding.
UBS Group first reported a position in Zymeworks in Q4 2017 and has held it in 33 quarters since.
UBS Group's Zymeworks position peaked at $7.34M in Q4 2025.
202 funds tracked by Wall St. Rank held Zymeworks as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.